CORONARY DISEASE IN ELDERLY PATIENTS – MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Abstract
Despite the fact that patients with acute myocardial infarction over age 75 represent a large subgroup with high mortality, most randomised clinical trials have included relatively few patients in this group. As a result, therapeutic recommendations for managing acute MI in the very elderly are often extrapolated from studies conducted in younger patients. This article reviews current guidelines of early treatment of acute myocardial infarction in the elderly. As in younger patients aspirin, beta blockers and angiotensinconverting enzyme inhibitors should be considered a standard therapy in appropriately selected patients. Although the benefits of reperfusion therapy (thrombolysis and primary angioplasty) are less well established, advanced age per se should not be considered a contraindication to the use of these interventions. Therapy should be individualised according to the patient’s clinical condition.Downloads
References
American Heart Association. Older Americans and cardiovascular disease. Statistical fact sheet – populations. Dostopno na: http://www.americanheart.org.
Cannon CP. Elderly patients with acute coronary syndromes; higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. Am J Geriatr Cardiol 2003; 12 (4): 259–62.
Tresch DD, Haritha RA. Diagnosis and management of myocardial ischemia (angina) in the elderly patient. Am J Geriatr Cardiol 2001; 10 (6): 337–44.
Stern S, Leor J, Harpaz D, Boyko V, Gottlieb S. Presenting symptoms, admission electrocardiogram, management and prognosis in acute coronary syndromes: differences by age. Am J Geriatr Cardiol 2004; 13 (4): 188–96.
Rich MW. Treatment of acute myocardial infarction. Am J Geriatr Cardiol 2001; 10 (6); 328–36.
Berger AK. Thrombolysis in elderly patients with acute myocardial infarction. Am J Geriatr Cardiol 2003; 12 (4): 251–6.
Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology /American Heart Association Task Force on Practical Guidelines. J Am Coll Cardiol 1999; 34 (3): 890–911.
White HD. Thrombolytic treatment in elderly. Lancet 2000; 356: 2028–30.
Rich MW. Thrombolytic therapy is indicated for patients over 75 years of age with ST elevation acute myocardial infarction: protagonist viewpoint. Am J Geriatr Cardiol 2003; 12 (6): 344–7.
Krumholtz HM, Friesinger GC, Cook EF et al. Thrombolytic therapy for eligible patients with acute myocardial infarction. JAMA 1997; 277: 1683–8.
Minai K, Horie H, Takajashi M, Nozawa M, Kinoshita M. Long-term outcome of primary percutaneous transluminal coronary angioplasty (PTCA) for lowrisk acute myocardial infarction (AMI) in patients older than 80 years: a single-center, open, randomized trial. Am Heart J 2002; 143 (3): 497–505.
Mehta RH, Stalhandske EJ, McCargar PA et al. Elderly patients at highest risk with acute myocardial infarction are more frequently transferred from community hospitals to tertiary centres: reality or myth? Am Heart J 1999; 138 (4): 688–95.
De Boer MJ, Ottervanger JP, van’t Hof AW. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002; 39: 1723–8.
Dauerman HL, Ryan TJ, Piper WD et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 2003; 15 (7): 380–4.
Prasad A, Lennon RJ, Rihal CS, Berger PB, Holmes DR. Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularisation. Am Heart J 2004; 147 (6): 1066–70.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
